Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed)
ID: 355993Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355993

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-026.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Investigating Mitochondrial-Nuclear Communication in AD/ADRD" (RFA-AG-25-026), aimed at supporting research into the interactions between mitochondrial and nuclear functions in the context of Alzheimer's disease (AD) and Alzheimer-related dementias (ADRD). This initiative seeks to enhance understanding of how mitochondrial-derived metabolites influence nuclear gene expression and cellular health, with the potential to inform future therapies targeting mitochondrial function in aging and neurodegeneration. The NIH plans to allocate up to $4 million in FY 2025 to fund eight research grants over five years, with applications due by November 8, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-25-026-Full-Announcement.html
    RFA-AG-25-026.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and its National Institute on Aging (NIA), has issued a Notice of Funding Opportunity (NOFO) titled "Investigating Mitochondrial-Nuclear Communication in AD/ADRD" (RFA-AG-25-026). This NOFO invites applications for R01 research grants focused on exploring the interactions between mitochondrial and nuclear functions in the context of Alzheimer's disease (AD) and Alzheimer-related dementias (ADRD). The goal is to enhance understanding of how mitochondrial-derived metabolites influence nuclear gene expression and cellular health within aging and neurodegenerative diseases. The funding opportunity will provide up to $4 million in FY 2025 to support eight awards over five years. Eligible applicants include higher education institutions, nonprofits, and for-profit organizations, among others, and applications are due by November 8, 2024. Research proposals should emphasize novel approaches to studying mitochondrial-nuclear communication and its implications for AD/ADRD, excluding projects that do not address these interactions. The review process will prioritize scientific merit, innovation, and potential public health impact. This initiative aligns with the NIH’s dedication to advancing research and therapy development in response to the growing Alzheimer's public health crisis.
    Similar Opportunities
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)." This grant aims to support innovative research that elucidates the molecular mechanisms and functional implications of RNA modifications in relation to brain aging and Alzheimer's disease (AD) and related dementias (ADRD), including Lewy body dementia and frontotemporal dementia. The initiative is crucial for advancing understanding in this field, with the ultimate goal of identifying biomarkers and therapeutic targets that could lead to improved health outcomes for affected populations. Eligible applicants can request up to $500,000 in direct costs per year for projects lasting a maximum of five years, with a total funding allocation of $4 million for fiscal year 2025. Applications are due by November 1, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Investigations into Alzheimer’s Disease-Related Dementias (ADRD) Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)." This grant aims to support research that investigates the interactions of multiple co-pathologies associated with ADRD, focusing on their cellular and molecular mechanisms and their impact on cognitive and functional impairments. The initiative is part of a broader commitment to advance neuroscience research and address public health challenges related to dementia, with particular emphasis on studies that explore co-pathologies such as tau and alpha-synuclein. Interested applicants can apply for funding up to $500,000, with applications due by October 4, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at catalyzing innovative research into the molecular mechanisms of RNA modifications related to brain aging and Alzheimer's disease (AD) and related dementias. This initiative seeks exploratory and developmental grant applications (R21) that focus on identifying critical RNA modification sites, understanding their functional impacts, and exploring gene regulation mechanisms relevant to aging and AD, with an emphasis on open-science practices and data sharing through the Alzheimer's Disease Knowledge Portal. Up to $1.4 million is available for five anticipated awards, with individual project budgets capped at $275,000 over a two-year period. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD)" through a U01 cooperative agreement mechanism. This initiative aims to support the optimization of promising genome editing-based therapeutic leads for ADRD, focusing on preparing these candidates for Investigational New Drug (IND)-enabling studies. The funding is crucial for advancing research in various forms of ADRD, including Frontotemporal Dementia and Lewy Body Dementia, by refining therapeutic candidates to ensure their safety and efficacy. Interested applicants can apply for up to $1 million in funding, with a total budget commitment of up to $3 million per year for two awards, and must submit their applications by November 19, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings," aimed at enhancing the understanding of Alzheimer’s Disease Related Dementias (ADRD). This initiative focuses on utilizing structural biology methodologies to investigate the relationships between protein structures and clinical outcomes of ADRD, specifically seeking to generate structural information on proteins implicated in the disease within their native cellular environments. The NIH plans to allocate up to $3 million annually for up to four grants, with each grant not exceeding $500,000 per year for a maximum of five years, contingent upon funding availability. Interested applicants can submit their proposals starting September 4, 2024, with a submission deadline of October 5, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment," aimed at investigating the impact of environmental risk factors (ERFs) on Alzheimer's Disease-Related Dementia (ADRD). This initiative seeks to explore how exogenous ERFs, such as toxins and pathogens, influence ADRD mechanisms at innervated human surfaces, including the gut, lungs, and skin, while explicitly prohibiting clinical trials. The NIH plans to allocate up to $3.75 million annually for this initiative, with individual project budgets capped at $500,000 over a maximum duration of five years. Applications are due by October 6, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced a funding opportunity titled "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD." This initiative invites applications that propose innovative strategies to target and manipulate specific brain cell subtypes associated with aging and neurodegenerative diseases, including Alzheimer's Disease and related dementias. The funding aims to support the development of advanced tools utilizing adeno-associated virus (AAV) capsid engineering and enhancer element identification, with a focus on mechanistic research rather than clinical trials. Up to $6 million is available for 6–8 awards, with applications due by October 8, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-024.html.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.